Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2022 | $34.00 → $36.00 | Buy | HC Wainwright & Co. |
| 11/2/2021 | $32.00 → $34.00 | Buy | HC Wainwright & Co. |
| 10/7/2021 | $32.00 | Buy | HC Wainwright & Co. |
8-K - Lantern Pharma Inc. (0001763950) (Filer)
8-K - Lantern Pharma Inc. (0001763950) (Filer)
10-Q - Lantern Pharma Inc. (0001763950) (Filer)
HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $36.00 from $34.00 previously
HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $34.00 from $32.00 previously
HC Wainwright & Co. initiated coverage of Lantern Pharma with a rating of Buy and set a new price target of $32.00
LP-184 achieves all primary endpoints and demonstrates a favorable safety and tolerability profile positioning it for both monotherapy or synergistic combinations with PARP inhibitors and immunotherapies. Clinical benefit observed in 48% of evaluable cancer patients at or above the therapeutic dose threshold. Durable clinical benefits were observed in hard-to-treat tumors like glioblastoma multiforme (GBM), gastrointestinal stromal tumor (GIST) and thymic carcinoma. Biomarker insights highlight potential in DDR-mutated cancers, with marked tumor reductions in patients with CHK2, ATM, and STK11/KEAP1 alterations. Recommended Phase 2 dose (RP2D) established for targeted Phase 1b/
AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Panna Sharma, President, CEO, and Director of Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using
Lantern Pharma Inc. (NASDAQ:LTRN), an AI-driven clinical -stage oncology company developing targeted therapies for cancer that are being advanced using its proprietary computational biology and machine learning platform, today announced the successful completion of a Type C meeting with the U.S. Food and Drug Administration (FDA). The meeting provided critical guidance on the regulatory pathway and trial design for a planned pediatric trial focused on CNS cancers, including Atypical Teratoid Rhabdoid Tumor (ATRT). During the Type C meeting, the FDA provided constructive feedback on the proposed clinical trial structure, which includes a parallel cohort specifically for ATRT patients to ac
4 - Lantern Pharma Inc. (0001763950) (Issuer)
4 - Lantern Pharma Inc. (0001763950) (Issuer)
4 - Lantern Pharma Inc. (0001763950) (Issuer)
Seasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member
DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate manufacturing and quality control. Darlene Bunpian, MPH has been appointed Clinical Trial Project Manag
Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025. Additional patient data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell lung cancer (NSCLC) anticipated in Q3 2025, including initial readout for patients from the Asian expansion cohort. Strengthened AI intellectual property portfolio with PCT publication of proprietary blood-brain barrier penetration prediction patent application; favorable PCT search report indicated no significant prior art. Expanded RADR® platform with innovative AI-powered module to improve the precision, cost and timeline of antibody
Webcast to be held Thursday, May 15th, 9:00 a.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its first quarter 2025 operating and financial results webcast on Thursday, May 15, 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. Management intends to discuss the operating and financial results for the first quarter ended March 31, 2025 and provide guidance on upcoming milestones, clinical tria
HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati
SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)
SC 13G/A - Lantern Pharma Inc. (0001763950) (Subject)
SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)